Literature DB >> 30547684

The GenMark ePlex®: another weapon in the syndromic arsenal for infection diagnosis.

Jonathan E Schmitz1, Yi-Wei Tang2,3.   

Abstract

As one of the most recent additions to the syndromic testing landscape, the ePlex® platform by GenMark Diagnostics is a system that combines the manufacturer's signature electrochemical detection technology with updated microfluidics, providing a new option for multiplex testing that is both rapid and requires minimal hands-on steps. In this review, we detail the ePlex platform and its current/future syndromic panels, with a particular focus on the respiratory pathogen panel - the platform's first assay to undergo clinical trials and receive regulatory approval in the USA. By keeping informed of these ever-expanding laboratory options, clinicians and microbiologists can stay positioned at the forefront of infectious disease diagnosis.

Entities:  

Keywords:  GenMark; ePlex; multiplex molecular testing; respiratory pathogen panel; syndromic infection testing

Mesh:

Year:  2018        PMID: 30547684      PMCID: PMC6439521          DOI: 10.2217/fmb-2018-0258

Source DB:  PubMed          Journal:  Future Microbiol        ISSN: 1746-0913            Impact factor:   3.165


  10 in total

Review 1.  Forty Years of Molecular Diagnostics for Infectious Diseases.

Authors:  Jonathan E Schmitz; Charles W Stratton; David H Persing; Yi-Wei Tang
Journal:  J Clin Microbiol       Date:  2022-07-19       Impact factor: 11.677

Review 2.  Appropriate Use and Future Directions of Molecular Diagnostic Testing.

Authors:  Erin H Graf; Preeti Pancholi
Journal:  Curr Infect Dis Rep       Date:  2020-02-06       Impact factor: 3.725

3.  Clinical Performance of the Novel GenMark Dx ePlex Blood Culture ID Gram-Positive Panel.

Authors:  Karen C Carroll; Jennifer L Reid; Adam Thornberg; Natalie N Whitfield; Deirdre Trainor; Shawna Lewis; Teresa Wakefield; Thomas E Davis; Keisha G Church; Linoj Samuel; Ray Mills; Patricia Jim; Stephen Young; Frederick S Nolte
Journal:  J Clin Microbiol       Date:  2020-03-25       Impact factor: 5.948

4.  Comparing the analytical performance of three SARS-CoV-2 molecular diagnostic assays.

Authors:  Katharine Uhteg; Junko Jarrett; Mahmia Richards; Craig Howard; Elizabeth Morehead; Melissa Geahr; Linda Gluck; Ann Hanlon; Brandon Ellis; Harsimar Kaur; Patricia Simner; Karen C Carroll; Heba H Mostafa
Journal:  J Clin Virol       Date:  2020-04-26       Impact factor: 3.168

5.  Development of an Online Tool for Pasteurella multocida Genotyping and Genotypes of Pasteurella multocida From Different Hosts.

Authors:  Zhong Peng; Junyang Liu; Wan Liang; Fei Wang; Li Wang; Xueying Wang; Lin Hua; Huanchun Chen; Brenda A Wilson; Jia Wang; Bin Wu
Journal:  Front Vet Sci       Date:  2021-12-17

6.  Digital Microfluidic qPCR Cartridge for SARS-CoV-2 Detection.

Authors:  Kuan-Lun Ho; Hong-Yu Liao; Helene Minyi Liu; Yen-Wen Lu; Pin-Kuan Yeh; Justin Yu Chang; Shih-Kang Fan
Journal:  Micromachines (Basel)       Date:  2022-01-27       Impact factor: 2.891

7.  The predictive potential of different molecular markers linked to amikacin susceptibility phenotypes in Pseudomonas aeruginosa.

Authors:  Wedad M Nageeb; Helal F Hetta
Journal:  PLoS One       Date:  2022-04-25       Impact factor: 3.752

Review 8.  Ethical surgical triage of patients with head and neck cancer during the COVID-19 pandemic.

Authors:  Francisco J Civantos; Jason M Leibowitz; David J Arnold; Vanessa C Stubbs; Jennifer H Gross; Giovana R Thomas; Zoukaa Sargi; Roy R Casiano; Elizabeth J Franzmann; Donald Weed; Cesar Perez; Michael Samuels; Kenneth W Goodman; W Jarrard Goodwin
Journal:  Head Neck       Date:  2020-05-21       Impact factor: 3.821

Review 9.  Plazomicin: a new aminoglycoside in the fight against antimicrobial resistance.

Authors:  Justin A Clark; David S Burgess
Journal:  Ther Adv Infect Dis       Date:  2020-09-04

Review 10.  Considerations for diagnostic COVID-19 tests.

Authors:  Olivier Vandenberg; Delphine Martiny; Olivier Rochas; Alex van Belkum; Zisis Kozlakidis
Journal:  Nat Rev Microbiol       Date:  2020-10-14       Impact factor: 78.297

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.